Dendritic Cell Activating Scaffold in Melanoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01753089 |
Recruitment Status :
Active, not recruiting
First Posted : December 20, 2012
Last Update Posted : January 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investigational vaccine, in this case WDVAX, to use for further studies. "Investigational" means that the vaccine is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not yet approved WDVAX for any use in patients, including people with Melanoma.
The purpose of this study is to determine if it is possible to make a vaccine against melanoma by using your own melanoma tumor cells and combining them with other proteins which activate the immune system. We hope that by combining the cells and the proteins in this way that the vaccine will cause your own immune system to react against your melanoma tumor cells. The purpose of this study is also to determine the safest way to give this vaccine with the least amount of side effects.
Each vaccine will contain your own tumor cells which have been killed by a freezing and thawing process which destroys the cells but keeps the proteins from the melanoma cells. This is called a "tumor lysate" Your tumor lysate is combined with other proteins which activate the immune system. The other proteins are called GM-CSF and CpG. All of this is held together to form a "tablet" or "scaffold" which is about the size of a regular aspirin tablet. The material that holds the protein together is called PLGA. PLGA is the same material that doctors use for "dissolvable stitches" If you have ever had a problem with these types of stitches in the past, be sure to let your study doctor know about this.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma | Biological: WDVAX | Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients |
Actual Study Start Date : | June 2013 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2023 |

Arm | Intervention/treatment |
---|---|
WDVAX
Treatment
|
Biological: WDVAX |
- Feasibility of WDVAX for Metastatic Melanoma [ Time Frame: 2 years ]To determine the feasibility of preparing dendritic cells activating scaffolds (WDVAX) incorporating autologous melanoma cell lysates in patients with metastatic melanoma
- Safety and Biologic Activity of WDVAX [ Time Frame: 2 years ]To determine the safety and biologic activity of vaccination with dendritic cell activation scaffolds (WDVAX) incorporating autologous melanoma cell lysates in patients with metastatic melanoma
- Immune Response [ Time Frame: 2 years ]
- Tumor Response [ Time Frame: 2 years ]
- Survival [ Time Frame: 2 years ]
- Response to subsequent immunotherapy (E.G., anit-CTLA-4 or anti_PD-1mAbs [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed Stage IV melanoma
- Life expectancy of 6 months or greater
- At least four weeks since treatment
- Recovered from any acute toxicity associated with prior therapy
- At least 8 weeks since treatment with any check point blockade agent
Exclusion Criteria:
- Known allergy or adverse reaction to PLG
- Pregnant or breastfeeding
- Receiving other investigational study agents
- Active autoimmune disease requiring treatment for suppression of inflammation
- Uncontrolled intercurrent illness
- History of a different malignancy unless disease-free for at least 5 years or diagnosed and treated cervical cancer in situ, basal or squamous cell carcinoma of the skin
- HIV positive

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01753089
United States, Massachusetts | |
Brigham and Women's Hospital | |
Boston, Massachusetts, United States, 02215 | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 |
Principal Investigator: | F. Stephen Hodi, MD | Dana-Farber Cancer Institute |
Responsible Party: | F. Stephen Hodi, MD, Principal Investigator, Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT01753089 |
Other Study ID Numbers: |
12-306 |
First Posted: | December 20, 2012 Key Record Dates |
Last Update Posted: | January 19, 2023 |
Last Verified: | January 2023 |
Metastatic |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |